Tilray partners with Coimbra University to study medical cannabis

The University of Coimbra has established a partnership with Tilray, Inc. (NASDAQ: TLRY) a specialist in the cultivation, production, and development of cannabis products.

The latest CBD and cannabis updates are now at your fingertips, with notifications and fresh information offered by our companion CBDNews app. Stay up-to-date with marijuana stocks for investments, global market, cannabis legalization and more.

University of Coimbra and Tilray partnership

Tilray and the University of Coimbra have established an unprecedented strategic partnership for research and to gain new knowledge, for the development of medical products derived from cannabis.

The Portuguese subsidiary of the Canadian company made a statement that “Combining Tilray’s vast experience in the cultivation, production, and development of cannabis products, this strategic partnership will be extended to various departments of the University of Coimbra, including opportunities for postgraduates in chemical, genetic and pharmaceutical sciences.”

The partnership will further medical cannabis research

The partnership will promote collaboration between Tilray “and the University’s academic leaders” on research projects, taking advantage of Tilray’s state-of-the-art campus and research facilities at the Biocant Technology Park, also located in Cantanhede. “We are proud to have established this partnership with the University of Coimbra and to collaborate with its vast team of specialists and researchers to study medical cannabis,” said Joshua Eades, Tilray’s scientific director.

During the signing session of the partnership in Coimbra, Eades added that the partnership with the UC “will allow the teams to collaborate in innovative research that contributes to the growth of science in cannabinoids, while also allowing the evolution of Tilray’s research and development program.”

UC business project

This session also served to launch the UC business project, which was created by the University in order to support the innovation and the provision of specialized services to public and private entities.

Tilray was the first medical cannabis producer to import medical cannabis products into the European Union successfully. They are also the first licensed medical cannabis producer in North America to achieve GMP certification according to the European Medicines Agency (EMA) standards.

Medical cannabis production

The Cantanhede work plant is the first in the country to produce medical cannabis, providing 200 jobs. It represented a total investment of $22 million (€20 million). Tilray de Cantanhede also serves as a support center for Tilray’s clinical research and product development efforts across Europe.

It benefits from the proximity of Biocant, the first biotechnology park in Portugal whose main objective is to sponsor, develop advanced knowledge in the area of life sciences, while also supporting high-potential business initiatives. The company is a global pioneer in the research, cultivation, production, and distribution of medical cannabis, and currently serves tens of thousands of patients and consumers in 12 countries across five continents.

__

(Featured image by SeaweedJeezus via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in TSF Rádio, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.